June 01, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Vunakizumab bests placebo in radiographic axial spondyloarthritis symptom improvement
Vunakizumab, a novel interleukin 17a monoclonal antibody, is superior to placebo in radiographic axial spondyloarthritis symptom improvement, according to data published in JAMA Network Open.“Nonsteroidal anti-inflammatory drugs (NSAIDs) are the recommended first-line pharmacologic treatment for [radiographic axial SpA (r-axSpA)],” Jian Zhu, MD, of the Chinese People’s
614 words~3 min read
